UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000031076
Receipt No. R000035487
Scientific Title Analysis of immune status in non-small cell lung cancer patients with EGFR mutations
Date of disclosure of the study information 2018/02/01
Last modified on 2019/09/10 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Analysis of immune status in non-small cell lung cancer patients with EGFR mutations
Acronym Analysis of immune status in NSCLC with EGFR mutations
Scientific Title Analysis of immune status in non-small cell lung cancer patients with EGFR mutations
Scientific Title:Acronym Analysis of immune status in NSCLC with EGFR mutations
Region
Japan

Condition
Condition non-small cell lung cancer
Classification by specialty
Pneumology Chest surgery Adult
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To elucidate immune status of non-small cell lung cancer patients with EGFR mutations who receive EGFR-TKIs
Basic objectives2 Others
Basic objectives -Others Search for biomarkers
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Changes of immune cells in tumor-infiltrating lymphocytes from pre- to post-treatment with EGFR-TKIs.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria All patients with advanced EGFR-mutated NSCLC receiving EGFR-TKIs as 1st line treatment whose tumor samples pre- and post-treatment are surplus will be enrolled in this study. Patients who already treated EGFR-TKI with archive samples will be also enrolled in this study.
Key exclusion criteria Patients who are not feasible for biopsy will be excluded.
Target sample size 30

Research contact person
Name of lead principal investigator
1st name Hiroyoshi
Middle name
Last name Nishikawa
Organization National Cancer Center
Division name Division of Cancer Immunology
Zip code 277-8577
Address 6-5-1 Kashiwanoha, Kashiwa, Chiba
TEL 0471331111
Email hnishika@ncc.go.jp

Public contact
Name of contact person
1st name Yosuke
Middle name
Last name Togashi
Organization National Cancer Center
Division name Division of Cancer Immunology
Zip code 277-8577
Address 6-5-1 Kashiwanoha, Kashiwa, Chiba
TEL 0471331111
Homepage URL
Email ytogashi1584@gmail.com

Sponsor
Institute National Cancer Center
Institute
Department

Funding Source
Organization AstraZeneca K.K.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization National Cancer Center
Address 6-5-1 Kashiwanoha
Tel 0471331111
Email irst@ml.res.ncc.go.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 国立がん研究センター東病院

Other administrative information
Date of disclosure of the study information
2018 Year 02 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2018 Year 02 Month 01 Day
Date of IRB
2018 Year 01 Month 16 Day
Anticipated trial start date
2018 Year 02 Month 01 Day
Last follow-up date
2021 Year 02 Month 28 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Immune status of tumor microenvironment is analyzed.

Management information
Registered date
2018 Year 01 Month 31 Day
Last modified on
2019 Year 09 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000035487